SAN FRANCISCO, August 06, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ...

All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated.

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

ECLIPSE 2 is one of three trials in Vir Biotechnology’s registrational ECLIPSE program for CHD, which was initiated in March 2025 .

Global Medical REIT Inc. Announces the Approval of a $50 Million Common Stock Repurchase Program and One-for-Five Reverse Stock Split ...

Chasity Pritchett empowers with olive oil and faith, promoting health and fighting chronic illness in Chesapeake through her innovative program.

"Should be overturned." First-of-its-kind lawsuit seeks to reverse sudden slashing of $3B program: 'Arbitrary and capricious' first appeared on The Cool Down.